Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ABBV

What Are Wall Street Analysts' Target Price for AbbVie Stock?

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Barchart

AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.

MarketBeat

AbbVie Earnings Preview: What to Expect

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years

While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.

Barchart

AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.

Apogee’s rally may be over, but AbbVie’s upside from the deal could just be getting started.

Barchart

The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

Barchart

AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

Barchart

Read news from The Economist, FT, and more,
with one subscription

AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.

Q1 earnings show this Dividend King still looks built for the long term.

Barchart

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

MarketBeat

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

AbbVie's early 2026 price pullback is an irresistable opportunity for buy-and-hold investors looking for income and compounding opportunities.

MarketBeat

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

These three Dividend Aristocrats offer yields above 3% and a history of consistent dividend growth, making them strong choices to help stay ahead of inflation.

MarketBeat

What You Need to Know Ahead of AbbVie’s Earnings Release

AbbVie will release its first-quarter earnings this month, and analysts anticipate a double-digit bottom-line growth.

Barchart

AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal

AbbVie is on track to grow, drive cash flow, and pay a healthy dividend for the long term: institutions and analysts are accumulating this stock.

MarketBeat

AbbVie Stock: Analyst Estimates & Ratings

After Humira’s patent cliff, what do analysts think about AbbVie’s stock now?

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

The 3 Most Reliable Dividend Stocks to Buy for Years to Come

These three dividend stocks are long-term winners with dependable payouts.

MarketBeat

AbbVie Call Options Spike 2,599%: Tracking the Big Bet

Large institutional investors are positioning for growth as a leading biopharmaceutical firm enters the obesity market and reaches a federal agreement.

Barchart

What to Expect From AbbVie's Next Quarterly Earnings Report

AbbVie will release its fourth-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

Barchart

2 Dividend Kings Quietly Beating the Market This Year

These two are the calm outperformers that might have been overlooked.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

3 Dividend Growth Stocks Analysts Are Upgrading for 2026

United Parcel Service, PepsiCo, and AbbVie are healthy dividend payers whose analyst trends support an outlook for price strength in 2026.

Barchart

3 Dividend Kings Delivering Generational Income & Market-Beating Returns

3 top-performing Dividend Kings of 2025 based on their Year-to-Date percent change.

Barchart

AbbVie’s (ABBV) Options Flow Implies That the Smart Money Could Be Up to Something

An intriguing quant signal combined with shifting sentiment in the derivatives market opens the possibility toward a bullish trade for ABBV stock.

MarketBeat

Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul

AbbVie, McDonald’s, and Walmart offer growth, rising dividends, and valuation upside as investors seek blue-chip stability heading into 2026

Barchart

Is AbbVie Stock Outperforming the Nasdaq?

AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

3 Dividend Aristocrats Every Diversified Portfolio Should Include

Win through diversification: mix stable, income-generating Dividend Aristocrats for growth, reliability, and long-term returns.

Barchart

1 High-Risk, High-Reward Way to Trade Earnings with 0DTE Options

Traders are increasingly turning to zero-days-to-expiration (0DTE) options to target fast-moving market reactions, including earnings announcements. The high leverage and compressed timeframe offered by these setups can deliver outsized returns, but those same dynamics leave little margin for error when it comes to timing and execution.

1 2 3 4 5

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.